Gp130 is expressed in pancreatic cancer and can be targeted by the small inhibitor molecule SC144
Open Access
- 10 December 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (1) , 271-280
Abstract
Purpose: Interleukin 6 (IL-6), Oncostatin M (OSM), and downstream effector STAT3 are pro-tumorigenic agents in pancreatic ductal adenocarcinoma (PDAC). Glycoprotein 130 (gp130) is a compound of the IL-6 and OSM receptor complex that triggers STAT3 signaling. SC144 is a small molecule gp130 inhibitor with anticancer activity. This study examines the gp130 expression in human PDAC specimens and the in vitro effects of SC144 in PDAC cell lines. Methods: Tissue micro-arrays were constructed from 175 resected human PDAC. The gp130 expression in tumor epithelium and stroma was determined by immunohistochemistry, and survival analysis was performed. Growth inhibition by SC144 was assessed in vitro using BrdU and MTT assays. Western blotting was performed to evaluate the SC144 effect on IL-6 and OSM signaling. Results: Gp130 was expressed in the epithelium of 78.8% and the stroma of 9.4% of the tumor samples. The median overall survival for patients with or without epithelial gp130 expression was 16.7 months and 15.9 months, respectively (p = 0.830). Patients with no stromal gp130 expression showed poorer survival than patients with stromal gp130 expression (median 16.2 and 22.9 months, respectively), but this difference did not reach significance (p = 0.144). SC144 inhibited cell proliferation and viability and suppressed IL-6- and OSM-stimulated STAT3Y705 phosphorylation in PDAC cells. Conclusion: Gp130 is expressed in the epithelium of most human PDAC, but stromal expression is rare. The small molecule gp130 inhibitor SC144 potently inhibits PDAC progression in vitro and may abrogate IL-6 or OSM/gp130/STAT3 signaling. These results suggest gp130 as a novel drug target for pancreatic cancer therapy.Keywords
Funding Information
- Stiftung Oskar-Helene-Heim (48)
- Charité - Universitätsmedizin Berlin
This publication has 32 references indexed in Scilit:
- Interleukin-6: from an inflammatory marker to a target for inflammatory diseasesTrends in Immunology, 2012
- Target Identification Using Drug Affinity Responsive Target Stability (DARTS)Current Protocols in Chemical Biology, 2011
- STAT3 Plays a Critical Role in KRAS-Induced Pancreatic TumorigenesisCancer Research, 2011
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic CancerCancer Cell, 2011
- Target identification using drug affinity responsive target stability (DARTS)Proceedings of the National Academy of Sciences, 2009
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- Combination effects of SC144 and cytotoxic anticancer agentsAnti-Cancer Drugs, 2009
- Interleukin‐6 Trans‐Signalling in Chronic Inflammation and CancerScandinavian Journal of Immunology, 2006
- Principles of interleukin (IL)-6-type cytokine signalling and its regulationBiochemical Journal, 2003
- Cytokines, the Acute-Phase Response, and Resting Energy Expenditure in Cachectic Patients with Pancreatic CancerAnnals of Surgery, 1994